leisure time -WSS

leisure time

author：comprehensive 2025-10-02 22:58:02 - browse：788

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： As pharma fights Medicare drug negotiation, hospitals, docs silent

WSS

The biotech scorecard for Q4: 16 stock

The stability of $0 premiums in Medicare Advantage

Will an HIV vaccine ever be a reality?

How to make Best Hospitals ratings actually useful for patients

Australia’s approach to dialysis celebrates life

What we owe ALS patients — and why one company fell short

explore

leisure time

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Study finds new variant for Parkinson’s in African populations

Bright Health sells Medicare Advantage business to Molina

IVG is promising — but it won’t replace IVF quite yet

Virginia high school admissions case could be legal follow

Diversity in medical illustrations gets boost from Chidiebere Ibe

In age of alternative facts, a scholarly course on calling out crap

Medicare explains how it will choose drugs for negotiation

In Memoriam: Notable people who died in 2023

Drug firms test therapies to halt Alzheimer’s before symptoms arise

knowledge

AstraZeneca challenges Medicare drug negotiation program

Medicare innovation center doesn’t save money, experts say

AstraZeneca bets AAV gene therapy will still deliver the goods

Appeals court upholds limits to abortion pill

FDA panel gives mixed vote on blood pressure devices

AstraZeneca bets AAV gene therapy will still deliver the goods

knowledge

leisure time

explore

Wikipedia